ArticleNeuro-oncology2008
New therapeutic approach for brain tumors: Intranasal delivery of telomerase inhibitor GRN163.
Article in Neuro-oncology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 4 syntheses or guidelines pooled it, 148 citations in OpenAlex.
- Advancements in Telomerase-Targeted Therapies for Glioblastoma: A Systematic Review.International journal of molecular sciences · 2024Pooled it
- Τelomerase inhibitors and activators in aging and cancer: A systematic review.Molecular medicine reports · 2022Pooled it
- Nanotechnology-based drug delivery systems for the treatment of Alzheimer's disease.International journal of nanomedicine · 2015Pooled it
- A systematic review of inhaled intranasal therapy for central nervous system neoplasms: an emerging therapeutic option.Journal of neuro-oncology · 2014Pooled it
- Locoregional Delivery of miRNAs for Glioblastoma Treatment: A Systematic Review of Advances in Delivery Systems.Pharmaceutics · 2026Review
- Intranasal Drug Delivery: Exploiting Nasal Anatomy for Enhanced Therapeutic Outcomes.Current pharmaceutical design · 2026Review
- Telomere Maintenance and DNA Repair: A Bidirectional Relationship in Cancer Biology and Therapy.Cancers · 2025Review
- In-depth Mechanism, Challenges, and Opportunities of Delivering Therapeutics in Brain Using Intranasal Route.AAPS PharmSciTech · 2024Review
- Blood-Brain Barrier Disruption for the Treatment of Primary Brain Tumors: Advances in the Past Half-Decade.Current oncology reports · 2024Review
- Drug Delivery of Solid Lipid Nanoparticles (SLNs) and Nanostructured Lipid Carriers (NLCs) to Target Brain Tumors.Advanced pharmaceutical bulletin · 2023Review
- Challenges in the Development and Application of Organ-on-Chips for Intranasal Drug Delivery Studies.Pharmaceutics · 2023Review
- Focused Delivery of Chemotherapy to Augment Surgical Management of Brain Tumors.Current oncology (Toronto, Ont.) · 2022Review
- Gene Targeting to the Cerebral Cortex Following Intranasal Administration of Polyplexes.Pharmaceutics · 2022Article
- Efficacy of Polymer-Based Nanomedicine for the Treatment of Brain Cancer.Pharmaceutics · 2022Review
- Intranasal drug delivery: opportunities and toxicologic challenges during drug development.Drug delivery and translational research · 2022Review
- Article
- Intranasal delivery: An attractive route for the administration of nucleic acid based therapeutics for CNS disorders.Frontiers in pharmacology · 2022Review
- Challenges and opportunities to penetrate the blood-brain barrier for brain cancer therapy.Theranostics · 2022Review
- Biomaterials for Drugs Nose-Brain Transport: A New Therapeutic Approach for Neurological Diseases.Materials (Basel, Switzerland) · 2021Review
- Advances in intranasal application of stem cells in the treatment of central nervous system diseases.Stem cell research & therapy · 2021Review
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
Abstract
The blood-brain barrier is a substantial obstacle for delivering anticancer agents to brain tumors, and new strategies for bypassing it are greatly needed for brain-tumor therapy. Intranasal delivery provides a practical, noninvasive method for delivering therapeutic agents to the brain and could provide an alternative to intravenous injection and convection-enhanced delivery. We treated rats bearing intracerebral human tumor xenografts intranasally with GRN163, an oligonucleotide N3'-->P5'thio-phosphoramidate telomerase inhibitor. 3'-Fuorescein isothiocyanate (FITC)-labeled GRN163 was administered intranasally every 2 min as 6 microl drops into alternating sides of the nasal cavity over 22 min. FITC-labeled GRN163 was present in tumor cells at all time points studied, and accumulation of GRN163 peaked at 4 h after delivery. Moreover, GRN163 delivered intranasally, daily for 12 days, significantly prolonged the median survival from 35 days in the control group to 75.5 days in the GRN163-treated group. Thus, intranasal delivery of GRN163 readily bypassed the blood-brain barrier, exhibited favorable tumor uptake, and inhibited tumor growth, leading to a prolonged lifespan for treated rats compared to controls. This delivery approach appears to kill tumor cells selectively, and no toxic effects were noted in normal brain tissue. These data support further development of intranasal delivery of tumor-specific therapeutic agents for brain tumor patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.